Equities Analysts Issue Forecasts for BCRX Q4 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities research analysts at HC Wainwright increased their Q4 2026 EPS estimates for shares of BioCryst Pharmaceuticals in a report released on Tuesday, June 30th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $0.14 per share for the quarter, up from their previous estimate of $0.09. HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($2.66) per share.

BCRX has been the subject of a number of other reports. Cantor Fitzgerald increased their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday. Citizens Jmp boosted their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Needham & Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Wedbush decreased their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $21.67.

BioCryst Pharmaceuticals Stock Up 4.7%

BCRX stock opened at $10.00 on Wednesday. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $10.94. The stock has a market cap of $2.54 billion, a price-to-earnings ratio of -5.62 and a beta of 0.57. The business has a fifty day moving average of $8.91 and a two-hundred day moving average of $8.29.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The business had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.20 earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BCRX. Vanguard Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after buying an additional 482,494 shares during the period. RA Capital Management L.P. purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at about $123,452,000. Deerfield Management Company L.P. boosted its holdings in BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after acquiring an additional 7,477,000 shares during the period. State Street Corp boosted its holdings in BioCryst Pharmaceuticals by 12.9% during the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock valued at $86,371,000 after acquiring an additional 1,265,773 shares during the period. Finally, Janus Henderson Group PLC grew its position in BioCryst Pharmaceuticals by 20.3% in the 1st quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock valued at $84,854,000 after acquiring an additional 1,504,120 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.